KCI USA is a biotechnology and healthcare startup that has been pioneering clinically proven and economically beneficial wound healing therapies and technologies since its founding in 1976. Their products are designed to deliver positive outcomes for patients and healthcare professionals by expediting the healing process, reducing complications, and improving patient lives.
The company has established key relationships globally, with their NPWT products being utilized in over 21,000 hospitals and skilled nursing facilities, as well as 11,000 home health agencies worldwide. In November 2011, KCI USA received a significant Post-IPO Equity investment from reputable investors such as Apax Partners, PSP Investments, and the Canada Pension Plan Investment Board.
With its strong focus on addressing critical healthcare needs and proven track record, KCI USA stands as a promising investment opportunity, positioned at the intersection of biotechnology and healthcare industries. Their extensive reach and proven impact make them a compelling venture for potential investors seeking opportunities in the healthcare sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | 3 |
|
04 Nov 2011 |
No recent news or press coverage available for KCI USA.
We care about your data, and we'd love to use cookies make your experience better.
